Celldex Therapeutics, Inc. (CLDX) Free cash flow 2016–2025
Celldex Therapeutics, Inc. (CLDX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$213.7MFY2025 · since FY2016: -$115.8M → -$213.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$213.7M | -33.8% |
| FY2024 | -$159.7M | -46.4% |
| FY2023 | -$109.1M | -3.4% |
| FY2022 | -$105.6M | -69.8% |
| FY2021 | -$62.2M | -48.2% |
| FY2020 | -$42.0M | +11.0% |
| FY2019 | -$47.1M | +38.0% |
| FY2018 | -$76.0M | +25.2% |
| FY2017 | -$101.7M | +12.1% |
| FY2016 | -$115.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CLDX financial trends
CLDX RevenueCLDX Net incomeCLDX Net marginCLDX Gross profitCLDX Gross marginCLDX Operating incomeCLDX Operating marginCLDX Operating cash flowCLDX Capital expendituresCLDX Return on equityCLDX Stock buybacksCLDX Dividends paidCLDX Total assetsCLDX Total liabilitiesCLDX Shareholders’ equityCLDX overview →